Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,261.00-1.06%ETH$2,465.93+0.26%GOLD$4,361.60-2.22%OIL$102.94+7.17%
Smart Investors Daily
MD

NASDAQ · MDGL

Madrigal Pharmaceuticals, Inc.

Healthcare · Biotechnology

$546.66

Down-$13.54 (-2.48%)

Updated Sep 10, 2026, 8:30 PM

SID Score

5.5/10

Composite research score

Smart Money

62/100

Neutral

Market cap
12.67B
P/E ratio
-45
Dividend yield
0.00%
52-week range
$393.61 – $615.00
Volume
281.26K
Avg. volume
340.65K

Price performance

MDGL price history

1M range · 20 trading sessions · Daily adjusted prices

MDGL closed at $546.66 after 20 trading sessions, up 1.95% for the selected period.

Last close
$546.66
Period change
+1.95%
Period low
$507.37
Period high
$546.93
Daily close
View OHLC price history
MDGL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$529.50$549.97$526.88$546.66281.26K
Sep 8, 2026$534.17$540.00$526.67$534.16199.46K
Sep 4, 2026$536.82$547.92$535.60$541.08177.17K
Sep 3, 2026$548.83$552.08$540.44$542.61143.46K
Sep 2, 2026$543.54$551.45$537.095$546.93202.82K
Sep 1, 2026$540.03$548.60$532.655$538.71165.75K
Aug 31, 2026$530.60$542.05$523.29$540.03134.58K
Aug 28, 2026$539.38$542.16$528.285$533.76268.66K
Aug 27, 2026$538.46$545.815$532.30$543.69221.85K
Aug 26, 2026$510.14$550.33$507.48$538.88345.54K
Aug 25, 2026$515.95$523.35$506.29$512.16189.2K
Aug 24, 2026$515.89$517.00$507.175$511.97145.52K
Aug 21, 2026$520.09$530.67$514.905$516.74179.83K
Aug 20, 2026$537.01$539.73$518.65$519.09264.48K
Aug 19, 2026$528.99$542.775$527.46$540.16221.13K
Aug 18, 2026$524.50$533.68$514.57$524.37356.2K
Aug 17, 2026$509.16$527.22$506.845$524.87307.44K
Aug 14, 2026$504.34$509.89$494.90$507.56234.66K
Aug 13, 2026$539.73$540.00$506.02$507.37277.89K
Aug 12, 2026$536.00$544.49$527.59$536.20285.55K

Latest MDGL news

The latest Smart Investors Daily articles mentioning MDGL.

Stock researchCompany · Overview

MDGL research

Overview

Company profile and research snapshot.

Company profile

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$595.40
Implied upside
—
Analysts
—
MDGL recent ratings
DateFirmRatingTarget
Aug 4, 2026Wolfe ResearchOutperform—
Aug 3, 2026BarclaysOverweight—
Jul 29, 2026Canaccord GenuityBuy—
Jul 27, 2026Wells FargoOverweight—
Jun 11, 2026B of A SecuritiesNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 20, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordan

Yahoo · Aug 15, 2026

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts. Speaking at a Canaccord Genuity event, C

Yahoo · Aug 12, 2026

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (“J&J”) and is a member of J&J’s Executive Committee, where he

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By